Logo image
Sign in
Back
Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up.
Journal article   Peer reviewed

Management of dyslipidaemia in high-risk patients with recent-onset rheumatoid arthritis: targets still not met despite specific recommendations. Results from the ESPOIR cohort during the first five years of follow-up.

Anne Tournadre, Bruno Pereira, Jean-Jacques Dubost, Nathalie Rincheval, Anne Christine Rat, Bernard Combe and Martin Soubrier
Clinical and experimental rheumatology, Vol.35(2), pp.296-302
03/2017
PMID: 28079508

Abstract

Adult Aged Biomarkers Cardiovascular Diseases Follow-Up Studies Cholesterol, LDL Cross-Sectional Studies Dyslipidemias Female France Guideline Adherence Humans Practice Guidelines as Topic Hypolipidemic Agents Lipids Male Middle Aged Prospective Studies Antirheumatic Agents Risk Assessment Risk Factors Time Factors Treatment Outcome Arthritis, Rheumatoid
Reduction of LDL-cholesterol (LDLc) is essential to decrease the cardiovascular mortality in rheumatoid arthritis (RA). Between 2005 and 2010, French recommendations for dyslipidaemia defined the LDLc target based on the number of cardiovascular risk factors. In 2006, it was recommended to consider LDLc objectives with RA being counted as an additional cardiovascular risk factor. Our objective was to assess lipid target achievement between 2006 and 2010 in a cohort of patients with recent-onset RA.
url
Find in HALView

Metrics

1 Record Views

Details

Logo image